Septicemia is a disease caused by the spread of bacteria and their toxins in the bloodstream. Also called blood poisoning and toxemia.
Nursing home infection rates are on the rise, a study from Columbia University School of Nursing found, suggesting that more must be done to protect residents of these facilities from preventable complications. The study, which examined infections in U.S. nursing homes over a five-year period, found increased infection rates for pneumonia, urinary tract infections (UTIs), viral hepatitis, septicemia, wound infections, and multiple drug-resistant organisms (MDROs).
Patients with sepsis, one of the most time-sensitive and hard-to-detect illnesses in medicine, are more likely to survive the life-threatening condition when treated at a hospital that sees a higher volume of sepsis cases.
The results of the research conducted in the ICAS Culiacán reveal that at least 10 percent of the fresh cheese, sausages and meats sold in markets and on the street may be contaminated.
Sanofi Pasteur, the vaccines division of Sanofi, presented Phase II (H-030-012) trial results for an investigational vaccine for the prevention of Clostridium difficile infection at the 114th General Meeting of the American Society for Microbiology.
Luminex Corporation today announced that Group B Streptococcus (group B strep, GBS) is the fifth assay planned for the launch menu of its new sample-to-answer system, ARIES™.
Septic shock is a severe systemic infection and major cause of death for the old and young alike. Unfortunately, researchers say testing new drug regimens to stop the infection is confounded because clinical trials include patients who are either too sick to be saved by experimental therapies or not sick enough to warrant the treatments.
Patient safety poses serious challenges to the health care system in the United States. Since 2001, nationwide efforts have focused on reducing in-hospital adverse events.
FDA & USDA announced today they have approved SALMONELEX as a "GRAS" (Generally Recognized as Safe) food processing aid against Salmonella. The new product consists of natural phages against Salmonella and is produced by Micreos of The Netherlands. The company confirms that industrial scale projects with US poultry processors will start in January 2014.
The annual incidence rates of primary diagnosed septicemia among active component service members increased nearly 580 percent from 2004 to 2012, according to a new study.
"Multiple hospitalizations for complications from a terminal illness may be burdensome for elderly patients and reflect poor quality care," write Joan M. Teno, M.D., M.S., of the Warren Alpert School of Medicine of Brown University, Providence, R.I., and colleagues, who conducted a study to examine whether the occurrence of multiple hospitalizations for the complications of infections or dehydration was associated with survival.
Pregnant women with diabetes are more than three times as likely as mothers without diabetes to become infected with methicillin-resistant Staphylococcus aureus (MRSA) before hospital discharge, according to a study in the July issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC).
Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted the Company's late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product indications, Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections.
The pathogen that we are talking about is called streptococcus pneumoniae. That is a fairly common bacteria and if you did a nasal swab you would find that quite a lot of people have this bacterium living in their nasal passages.
The drug-resistant bacteria known as MRSA, once confined to hospitals but now widespread in communities, will likely continue to exist in both settings as separate strains, according to a new study.
Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the company's late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product (QIDP) for the indications of Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI).
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
Postoperative complications occur in more than three-quarters of patients who have a cardiac arrest, shows research that suggests an opportunity for intervention.
Patients with severe mental illness are at increased risk for pneumococcal disease, results from a UK study suggest.
Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated two of the company's Phase 3 antibiotic candidates, CXA-201 (ceftolozane/tazobactam) and CB-315, as Qualified Infectious Disease Products (QIDP).
New mass spectrometry technology is helping Le Bonheur Children's physicians analyze microbiology samples quickly - identifying specific bacteria present in a sample within minutes.